On the fly News and insights, exclusive to thefly.com



$4.30 /

+0.275 (+6.83%)


Novavax price target raised to $17 from $10 at H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino raised his price target for Novavax to $17 from $10 and reiterates a Buy rating on the shares. The stock closed yesterday up 28c to $4.30. The agreement on a Phase 3 trial design for NanoFlu that Novavax announced with the FDA on August 5 sets the stage for the program to accelerate, Bernardino tells investors in a research note. The analyst believes Novavax's NanoFlu vaccine can now be approved in 2022 versus his prior expectation of 2024. He looks for share price appreciation to allow "successful financings" in 2020 and 2021, positioning Novavax to independently launch commercial NanoFlu worldwide.

NVAX Novavax
$4.30 /

+0.275 (+6.83%)

07/01/19 H.C. Wainwright
Novavax price target raised to $12 from $10 at H.C. Wainwright
06/28/19 Oppenheimer
Novavax addressed 2 of 3 'big unknowns' this week, says Oppenheimer
05/13/19 Oppenheimer
Novavax price target raised to $25 from $1.25 at Oppenheimer
05/06/19 Citi
Citi recommends buying Novavax ahead of regulatory update

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.